---
document_datetime: 2026-01-19 16:53:55
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/brintellix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: brintellix-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.4140018
conversion_datetime: 2026-01-20 20:09:53.68422
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.69.0
  docling-core: 2.60.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Brintellix

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                              |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------|
| Variation type II /  | C.I.3 Change(s) in the Summary of Product | 27/11/2025                          |                                             | SmPC and PL                      | Update of section 4.6 of the SmPC in order to revise |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000296460                        | Characteristics, Labelling or Package Leaflet of human medicinal products intended to implement the outcome of a procedure concerning PSUR or PASS, or the outcome of the assessment done by the competent authority under Articles 45 or 46 of Regulation 1901/2006 - C.I.3.b Implementation of change(s) which require to be further substantiated by new additional data to be submitted by the MAH - Accepted Update of section 4.6 of the summary of product characteristics (SmPC) in order to revise information regarding lactation, following the PRAC Assessment Report for PSUSA/00010052/20240. The package leaflet (PL) is updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the   |            |             | information regarding lactation. The PL is updated accordingly.                                                                                                                                                               |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Variation type IA_IN / EMA/VR/0000290437 | C.I HUMAN AND VETERINARY MEDICINAL PRODUCTS - C.I.z Change(s) in the Summary of product Characteristics, Labelling or Package Leaflet intended to implement the outcome of a PRAC signal recommendation: implementation of wording agreed by the competent authority that do not require any further assessment - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                  | 07/08/2025 | SmPC and PL | To update Section 4.8 of the SmPC and Section 4 of the PL to implement the signal recommendation on 'Vortioxetine - Hallucinations, not related to serotoninergic syndrome' (EPITT no 20152) adopted at the 5 June 2025 PRAC. |